Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Weekly News Recap #Phispers
1. Azd-9291
2. Azd-9291 Mesylate
3. Azd9291
4. Azd9291 Mesylate
5. Mereletinib
6. Mereletinib Mesilate
7. Mereletinib Mesylate
8. N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-2-propenamide
9. N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-2-propenamide Methanesulfonate (1:1)
10. Osimertinib
11. Osimertinib Mesilate
12. Tagrisso
1. 1421373-66-1
2. Azd-9291 Mesylate
3. Azd9291 Mesylate
4. Azd-9291 (mesylate)
5. Mereletinib Mesylate
6. Tagrisso
7. Osimertinib Mesilate
8. Mereletinib Mesilate
9. Osimertinib Mesylate [usan]
10. Rdl94r2a16
11. N-[2-[2-(dimethylamino)ethyl-methylamino]-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide;methanesulfonic Acid
12. N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide Methanesulfonate
13. Osimertinib Mesilate (jan)
14. Osimertinib Mesylate (usan)
15. 2-propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-, Methanesulfonate (1:1)
16. Osimertinib Mesilate [jan]
17. 2-propenamide, N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1h-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-, Compd. With Methanesulfonate (1:2)
18. Unii-rdl94r2a16
19. Tagrisso (tn)
20. Osimertinib Monomesylate
21. Azd 9291 Mesylate
22. Osimertinib Methanesulfonate
23. Amy226
24. Chembl3545063
25. Schembl14661152
26. Chebi:90948
27. Osimertinib Mesylate [mi]
28. Dtxsid101027822
29. Bcp09934
30. Ex-a1577
31. Hy-15772a
32. Mfcd28137994
33. Osimertinib Mesilate [who-dd]
34. Akos026673944
35. Ds-9913
36. Sb22953
37. Ac-29022
38. Da-35303
39. Osimertinib Mesylate [orange Book]
40. Azd-9291 Mesylate (osimertinibmereletinib)
41. Ft-0699962
42. S5078
43. D10766
44. Q27162942
45. Azd9291 Ms Salt, Osimertinib Ms Salt; Mereletinib Ms Salt
46. N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide Methanesulfonate
47. N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1h-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide Methanesulfonate
1. Osimertinib
Molecular Weight | 595.7 g/mol |
---|---|
Molecular Formula | C29H37N7O5S |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 10 |
Rotatable Bond Count | 10 |
Exact Mass | 595.25768848 g/mol |
Monoisotopic Mass | 595.25768848 g/mol |
Topological Polar Surface Area | 150 Ų |
Heavy Atom Count | 42 |
Formal Charge | 0 |
Complexity | 845 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
TAGRISSO as monotherapy is indicated for:
-the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations
- the first-line treatment of adult patients NSCLC with activating EGFR mutations.
- the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.
TAGRISSO as monotherapy is indicated for:
- the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.
- the first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR mutations.
- the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Protein Kinase Inhibitors
Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)
L01XE
Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.
Faran Shimi: Leading producer of high-quality APIs & alkaloid opiates, serving major pharmaceutical companies across the Middle East.
Aarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.
Sichuan Elixir Pharmaceutical, a manufacturer of small molecule APIs & a CMO/CDMO service provider for anti-tumor characteristic APIs..
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
GDUFA
DMF Review : Reviewed
Rev. Date : 2019-05-06
Pay. Date : 2019-03-14
DMF Number : 32143
Submission : 2017-12-29
Status : Active
Type : II
Date of Issue : 2022-09-02
Valid Till : 2025-05-05
Written Confirmation Number : WC-0349
Address of the Firm :
NDC Package Code : 54893-0068
Start Marketing Date : 2017-12-29
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Pharmapia Co., Ltd.
Registration Date : 2024-12-19
Registration Number : No. 173-37-ND(1)
Manufacturer Name : MSN Laboratories Private Limited
Manufacturer Address : (Unit-ll) Sy. No. 50, 53, 53/A, 54 & 54/A, Kardanur (Village), Patancheru (Mandal), Sangareddy District, Telangana, Pincode: 502 300, India.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36546
Submission : 2021-12-24
Status : Active
Type : II
NDC Package Code : 54245-1451
Start Marketing Date : 2022-06-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35581
Submission : 2021-02-04
Status : Active
Type : II
Registrant Name : Lihu Healthcare Co., Ltd.
Registration Date : 2024-03-18
Registration Number : Thu21-24-ND(1)
Manufacturer Name : Hetero Labs Limited(Unit-1)
Manufacturer Address : Survey No.10, IDA, Gaddapotharam Village, Jinnaram Mandal, SangaReddy District.-502319, Telangana, India
GDUFA
DMF Review : Complete
Rev. Date : 2019-02-26
Pay. Date : 2018-12-12
DMF Number : 33409
Submission : 2018-12-31
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35581
Submission : 2021-02-04
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2019-05-06
Pay. Date : 2019-03-14
DMF Number : 32143
Submission : 2017-12-29
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36546
Submission : 2021-12-24
Status : Active
Type : II
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Global Sales Information
Company :
Osimertinib Mesylate
Drug Cost (USD) : 1,081,280,466
Year : 2022
Prescribers : 8629
Prescriptions : 64678
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Osimertinib Mesylate
Drug Cost (USD) : 913,265,970
Year : 2021
Prescribers : 7780
Prescriptions : 56038
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Osimertinib Mesylate
Drug Cost (USD) : 793,479,172
Year : 2020
Prescribers : 7016
Prescriptions : 49761
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Osimertinib Mesylate
Drug Cost (USD) : 640,665,670
Year : 2019
Prescribers : 6471
Prescriptions : 41212
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Osimertinib Mesylate
Drug Cost (USD) : 387,940,690
Year : 2018
Prescribers : 4586
Prescriptions : 25308
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Osimertinib Mesylate
Drug Cost (USD) : 189,639,073
Year : 2017
Prescribers : 2321
Prescriptions : 12787
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Osimertinib Mesylate
Drug Cost (USD) : 125,850,146
Year : 2016
Prescribers : 1559
Prescriptions : 9143
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Osimertinib Mesylate
Drug Cost (USD) : 4,670,268
Year : 2015
Prescribers : 263
Prescriptions : 351
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 4,328
2019 Revenue in Millions : 3,189
Growth (%) : 36
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 5,015
2020 Revenue in Millions : 4,328
Growth (%) : 16
Main Therapeutic Indication : Oncology
Currency : USD
2022 Revenue in Millions : 5,444
2021 Revenue in Millions : 5,015
Growth (%) : 9
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 5,799
2022 Revenue in Millions : 5,444
Growth (%) : 7
Main Therapeutic Indication : Oncology
Currency : USD
2015 Revenue in Millions : 0
2014 Revenue in Millions : 19
Growth (%) : New Launch
Main Therapeutic Indication : Oncology
Currency : USD
2017 Revenue in Millions : 955
2016 Revenue in Millions : 423
Growth (%) : 126
Main Therapeutic Indication : Oncology
Currency : USD
2018 Revenue in Millions : 1,860
2017 Revenue in Millions : 955
Growth (%) : 95%
Main Therapeutic Indication : Oncology
Currency : USD
2016 Revenue in Millions : 423
2015 Revenue in Millions : 19
Growth (%) : 2,126
Main Therapeutic Indication : Oncology
Currency : USD
2019 Revenue in Millions : 3,189
2018 Revenue in Millions : 1,860
Growth (%) : 71
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Osimertinib Mesylate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Osimertinib Mesylate, including repackagers and relabelers. The FDA regulates Osimertinib Mesylate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Osimertinib Mesylate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Osimertinib Mesylate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Osimertinib Mesylate supplier is an individual or a company that provides Osimertinib Mesylate active pharmaceutical ingredient (API) or Osimertinib Mesylate finished formulations upon request. The Osimertinib Mesylate suppliers may include Osimertinib Mesylate API manufacturers, exporters, distributors and traders.
click here to find a list of Osimertinib Mesylate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Osimertinib Mesylate DMF (Drug Master File) is a document detailing the whole manufacturing process of Osimertinib Mesylate active pharmaceutical ingredient (API) in detail. Different forms of Osimertinib Mesylate DMFs exist exist since differing nations have different regulations, such as Osimertinib Mesylate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Osimertinib Mesylate DMF submitted to regulatory agencies in the US is known as a USDMF. Osimertinib Mesylate USDMF includes data on Osimertinib Mesylate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Osimertinib Mesylate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Osimertinib Mesylate suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Osimertinib Mesylate Drug Master File in Korea (Osimertinib Mesylate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Osimertinib Mesylate. The MFDS reviews the Osimertinib Mesylate KDMF as part of the drug registration process and uses the information provided in the Osimertinib Mesylate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Osimertinib Mesylate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Osimertinib Mesylate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Osimertinib Mesylate suppliers with KDMF on PharmaCompass.
A Osimertinib Mesylate written confirmation (Osimertinib Mesylate WC) is an official document issued by a regulatory agency to a Osimertinib Mesylate manufacturer, verifying that the manufacturing facility of a Osimertinib Mesylate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Osimertinib Mesylate APIs or Osimertinib Mesylate finished pharmaceutical products to another nation, regulatory agencies frequently require a Osimertinib Mesylate WC (written confirmation) as part of the regulatory process.
click here to find a list of Osimertinib Mesylate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Osimertinib Mesylate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Osimertinib Mesylate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Osimertinib Mesylate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Osimertinib Mesylate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Osimertinib Mesylate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Osimertinib Mesylate suppliers with NDC on PharmaCompass.
Osimertinib Mesylate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Osimertinib Mesylate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Osimertinib Mesylate GMP manufacturer or Osimertinib Mesylate GMP API supplier for your needs.
A Osimertinib Mesylate CoA (Certificate of Analysis) is a formal document that attests to Osimertinib Mesylate's compliance with Osimertinib Mesylate specifications and serves as a tool for batch-level quality control.
Osimertinib Mesylate CoA mostly includes findings from lab analyses of a specific batch. For each Osimertinib Mesylate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Osimertinib Mesylate may be tested according to a variety of international standards, such as European Pharmacopoeia (Osimertinib Mesylate EP), Osimertinib Mesylate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Osimertinib Mesylate USP).
LOOKING FOR A SUPPLIER?